Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) have been assigned a consensus recommendation of “Hold” from the seven brokerages that are covering the stock. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $26.84.

Several brokerages recently issued reports on DVAX. Cowen and Company reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Dynavax Technologies Corp. in a report on Tuesday, September 6th. Zacks Investment Research raised Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a report on Monday, June 27th. RBC Capital Markets reaffirmed a “sector perform” rating and set a $16.00 price objective on shares of Dynavax Technologies Corp. in a report on Wednesday, September 7th. Finally, William Blair reaffirmed a “buy” rating and set a $45.00 price objective on shares of Dynavax Technologies Corp. in a report on Tuesday, September 6th.

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) traded up 0.19% during trading on Thursday, hitting $10.68. 440,945 shares of the stock traded hands. The firm’s market cap is $411.15 million. The stock has a 50 day moving average of $12.42 and a 200 day moving average of $15.54. Dynavax Technologies Corp. has a 52-week low of $10.11 and a 52-week high of $29.86.

Dynavax Technologies Corp. (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.07. The firm had revenue of $2.65 million for the quarter, compared to analyst estimates of $1.58 million. Dynavax Technologies Corp. had a negative return on equity of 64.43% and a negative net margin of 2,068.75%. The business’s revenue for the quarter was up 70.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.80) earnings per share. Analysts expect that Dynavax Technologies Corp. will post ($2.96) EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Boston Advisors LLC increased its stake in shares of Dynavax Technologies Corp. by 1.3% in the second quarter. Boston Advisors LLC now owns 12,330 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 155 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Dynavax Technologies Corp. by 1.9% in the second quarter. Royal Bank of Canada now owns 19,471 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 363 shares in the last quarter. Boston Partners increased its stake in shares of Dynavax Technologies Corp. by 0.4% in the second quarter. Boston Partners now owns 123,378 shares of the biopharmaceutical company’s stock worth $1,799,000 after buying an additional 498 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Dynavax Technologies Corp. by 19.2% in the first quarter. Legal & General Group Plc now owns 6,235 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 1,003 shares in the last quarter. Finally, American International Group Inc. increased its stake in shares of Dynavax Technologies Corp. by 5.2% in the second quarter. American International Group Inc. now owns 22,375 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 1,107 shares in the last quarter. 83.82% of the stock is owned by institutional investors.

About Dynavax Technologies Corp.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Receive News & Stock Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related stocks with our FREE daily email newsletter.